Glenn Lesser to Combined Modality Therapy
This is a "connection" page, showing publications Glenn Lesser has written about Combined Modality Therapy.
Connection Strength
0.708
-
Renfrow JJ, Strowd RE, Laxton AW, Tatter SB, Geer CP, Lesser GJ. Surgical Considerations in the Optimal Management of Patients with Malignant Brain Tumors. Curr Treat Options Oncol. 2017 08; 18(8):46.
Score: 0.137
-
Renfrow JJ, Lesser GJ. Molecular subtyping of brain metastases and implications for therapy. Curr Treat Options Oncol. 2013 Dec; 14(4):514-27.
Score: 0.106
-
Strowd RE, Blackwood R, Brown M, Harmon M, Lovato J, Yalcinkaya T, Lesser G. Impact of temozolomide on gonadal function in patients with primary malignant brain tumors. J Oncol Pharm Pract. 2013 Dec; 19(4):321-7.
Score: 0.100
-
Peacock KH, Lesser GJ. Current therapeutic approaches in patients with brain metastases. Curr Treat Options Oncol. 2006 Nov; 7(6):479-89.
Score: 0.065
-
Klepin HD, McMullen KP, Lesser GJ. Esthesioneuroblastoma. Curr Treat Options Oncol. 2005 Nov; 6(6):509-18.
Score: 0.061
-
Yalamanchili M, Lesser GJ. Malignant spinal cord compression. Curr Treat Options Oncol. 2003 Dec; 4(6):509-16.
Score: 0.053
-
Ramkissoon LA, Britt N, Guevara A, Whitt E, Severson E, Sathyan P, Gay L, Elvin J, Ross JS, Brown C, Stogner-Underwood K, Mott R, Kram D, Strowd R, Lesser GJ, Ramkissoon SH. Precision Neuro-oncology: the Role of Genomic Testing in the Management of Adult and Pediatric Gliomas. Curr Treat Options Oncol. 2018 06 21; 19(8):41.
Score: 0.036
-
Lucas JT, Huang AJ, Mott RT, Lesser GJ, Tatter SB, Chan MD. Anaplastic ganglioglioma: a report of three cases and review of the literature. J Neurooncol. 2015 May; 123(1):171-7.
Score: 0.029
-
Mirlohi S, Duncan SE, Harmon M, Case D, Lesser G, Dietrich AM. Analysis of salivary fluid and chemosensory functions in patients treated for primary malignant brain tumors. Clin Oral Investig. 2015 Jan; 19(1):127-37.
Score: 0.027
-
Nabors LB, Mikkelsen T, Hegi ME, Ye X, Batchelor T, Lesser G, Peereboom D, Rosenfeld MR, Olsen J, Brem S, Fisher JD, Grossman SA. A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306). Cancer. 2012 Nov 15; 118(22):5601-7.
Score: 0.024
-
Rosenfeld MR, Chamberlain MC, Grossman SA, Peereboom DM, Lesser GJ, Batchelor TT, Desideri S, Salazar AM, Ye X. A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma. Neuro Oncol. 2010 Oct; 12(10):1071-7.
Score: 0.021
-
Lustig R, Mikkelsen T, Lesser G, Grossman S, Ye X, Desideri S, Fisher J, Wright J. Phase II preradiation R115777 (tipifarnib) in newly diagnosed GBM with residual enhancing disease. Neuro Oncol. 2008 Dec; 10(6):1004-9.
Score: 0.018
-
Grossman SA, Olson J, Batchelor T, Peereboom D, Lesser G, Desideri S, Ye X, Hammour T, Supko JG. Effect of phenytoin on celecoxib pharmacokinetics in patients with glioblastoma. Neuro Oncol. 2008 Apr; 10(2):190-8.
Score: 0.018
-
Shaw EG, Tatter SB, Lesser GJ, Ellis TL, Stanton CA, Stieber VW. Current controversies in the radiotherapeutic management of adult low-grade glioma. Semin Oncol. 2004 Oct; 31(5):653-8.
Score: 0.014